Table 3 No (%) patients with RA during the ARMADA trial and open label extension with no signs of joint involvement (TJC = 0, SJC = 0), normal CRP (<8 mg/l), ACR70 response, clinical remission based on DAS28 <2.6, clinically meaningful improvements in HAQ score (HAQ reduction ⩾–0.22), and normal functional status (HAQ = 0).
| Variable | Months | ||||
|---|---|---|---|---|---|
| 6 (n = 221) | 12 (n = 176) | 24 (n = 196) | 36 (n = 176) | 48 (n = 147) | |
| TJC68 = 0* | 40 (18) | 32 (18) | 48 (24) | 43 (24) | 42 (28) |
| SJC66 = 0* | 33 (15) | 37 (21) | 52 (26) | 42 (23) | 33 (22) |
| CRP <8 mg/l* | 146 (66) | 141 (78) | 144 (73) | 126 (71) | 110 (74) |
| ACR70 | 53 (24) | 54 (31) | 64 (33) | 56 (32) | 46 (31) |
| DAS <2.6 | 71 (32) | 60 (34) | 74 (38) | 67 (38) | 63 (43) |
| HAQ reduction ⩾–0.22 | 179 (81) | 145 (82) | 159 (80) | 141 (80) | 118 (81) |
| HAQ = 0 | 33 (14) ) | 30 (17) | 42 (21) | 42 (24) | 31 (22) |
Results are shown as No (%).
*For these efficacy measures, 1–3 additional patients were available for analysis. The number of patients at the top of each column indicates the number of patients for whom all six efficacy measures were available at that time point.